^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    paxalisib (GDC-0084)

    i
    Company:
    Kazia, QIMR Berghofer Medical Research Institute, Roche, Simcere, SoVarGen
    Drug class:
    mTOR inhibitor, PI3K inhibitor, AKT inhibitor
    Related drugs:
    Apply
    Genetic Testing in Guiding Treatment for Patients with Brain Metastases (NCT03994796)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    01/15/2025
    Initiation :
    10/17/2019
    Primary completion :
    10/01/2026
    Completion :
    06/01/2028
    KRAS • BRAF • ER • PGR • ROS1 • NTRK
    |
    HER-2 positive • EGFR mutation • HER-2 negative
    |
    Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)
    Combination Therapy for the Treatment of Diffuse Midline Gliomas (NCT05009992)
    Phase 2
    University of California, San Francisco
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    10/20/2021
    Primary completion :
    12/31/2025
    Completion :
    06/30/2029
    BRAF
    |
    dordaviprone (ONC201) • paxalisib (GDC-0084)
    GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases (NCT03765983)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    02/11/2019
    Primary completion :
    11/30/2024
    Completion :
    11/30/2025
    HER-2 • EIF4EBP1
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • paxalisib (GDC-0084)
    GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases (NCT04192981)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    04/17/2024
    Initiation :
    12/06/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3
    |
    paxalisib (GDC-0084)
    Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma (NCT05183204)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    09/26/2023
    Initiation :
    02/14/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    MGMT
    |
    MGMT promoter methylation
    |
    metformin • paxalisib (GDC-0084)